Supera™ Stent

Results Matter. Platform Matters.

  Supera Stent

Unmatched 1-Year Patency & 3-Year Freedom From TLR

The Supera™ Stent has been studied in over 2,000 patients worldwide in the SUPERB trial and 16 retrospective studies. Notably, in all of the 17 studies, the Supera™ Peripheral Stent showed durable results with zero fractures at 1 year.1,4-19


At 1 year the Supera™ Stent demonstrated primary patency of 91% when nominally* deployed. At 3 years, freedom from targeted lesion revascularization (TLR) was 94% when nominally* deployed.1

  91% patency at 1 year


When nominally deployed*

  94% freedom from TLR at 3 years


When nominally deployed*

*Nominal deployment is defined as the stent length upon deployment being within +/- 10% of the labeled stent length. This data is from a non-powered post-hoc analysis. K-M=Kaplan Meier.

Consistent Patency Regardless of Lesion Length

With some peripheral stents, increasing lesion lengths can lead to decreasing patency rates.20 The Supera™ Stent stands apart for its consistently high patency rates in lesions spanning lengths from 5.3 cm up to 28.0 cm.

  consistently high patency rates

Published data was included if lesion length and patency were both available.

Note: Results from different clinical trials are not directly comparable. Information provided for educational purposes only.

Excellent Results from Simple to Complex Lesions

Whether treating simple (TASC A&B) or complex (TASC C&D) lesions, the Supera™ Stent is associated with impressive, consistent patency performance data at 1 year.1-4


Simple lesionTrial/StudyMUNICH REGISTRY2SUPERB1
Lesion Length5.3cm7.8cm
TASC A&B Lesions100%94%
SitesSingle CenterMulticenter (46 sites)
# Patients70264


Complex LesionTrial/StudyST. LOUIS4SUPERSUB3
Lesion Length24cm28cm
TASC C&D Lesions78%100%
SitesSingle CenterSingle Center
# Patients4834

TASC: Trans-Atlantic Inter-Society Consensus


  1. Garcia L. et al., Catheterization and Cardiovascular Interventions 2017 Jun 1;89(7):1259-1267.
  2. Treitl, K.M., et al. European Radiology.2017; 10.1007.
  3. Palena L.M. et al. Catheterization and Cardiovascular Intervention.2016.
  4. Brescia AA. et al., J Vasc Surg. 2015 Jun;61(6):1472-8
  5. George JC. et al., J Vasc Interv Radiol. 2014 Jun;25(6):954-61.
  6. Montero-Baker M. et al., J Vasc Surg. 2016 Oct;64(4):1002-8.
  7. Scheinert D. et al., J Endovasc Ther. 2011 Dec;18(6):745-52.
  8. Werner M. et al., EuroIntervention. 2014 Nov;10(7):861-8.
  9. San Norberto EM. et al., Ann Vasc Surg. 2017 May;41:186-195.
  10. Chan YC. et al., J Vasc Surg. 2015 Nov;62(5):1201-9.
  11. Dumantepe M. Vasc Endovascular Surg. 2017 Jul;51(5):240-246.
  12. Goltz JP. et al., J Endovasc Ther. 2012 Jun;19(3):450-6.
  13. León LR Jr. et al., J Vasc Surg. 2013 Apr;57(4):1014-22.
  14. Myint M. et al., J Endovasc Ther. 2016 Jun;23(3):433-41.
  15. Palena LM. et al., J Endovasc Ther. 2018 Oct;25(5):588-591.
  16. Scheinert D. et al., JACC Cardiovasc Interv. 2013 Jan;6(1):65-71.
  17. Steiner S. et al., J Endovasc Ther. 2016 Apr;23(2):347-55.
  18. Teymen B. et al., Vascular. 2018 Feb;26(1):54-61.
  19. Bhatt H. et al., Cardiovasc Revasc Med. 2018 Jul;19(5 Pt A):512-515.
  20. Shroë H. Superficial femoral artery PTA or stenting? 5-Year results. CIRSE 2011; Munich, Germany

MAT-2106532 v2.0